AviadoBio

Revolution in gene therapy for neurodegenerative disorders

AviadoBio’s mission is to transform the lives of patients living with and suffering from neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

CEO  Lisa Deschamps

Advent Contact  Dominic Schmidt

Private Companies
12 September 2022 in AviadoBio, Press Release, Private Companies

AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner

Press Release.   AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner Award reinforces AviadoBio’s position as one of the most promising early-stage biotech companies in the gene…
Read More
4 May 2022 in AviadoBio, Press Release, Private Companies

AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

Press Release.   Intrathalamic delivery of AVB-101 shows promising efficacy in a pre-clinical disease model Gene therapy candidate also demonstrated broad cortical expression in a large animal biodistribution study  …
Read More
2 December 2021 in AviadoBio, Press Release, Private Companies

AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

Press Release.   Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows seeding by Advent Life Sciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson &…
Read More